Core Viewpoint - The company, Guichuang Tongqiao, reported significant revenue growth driven by its neurovascular and peripheral vascular intervention products, with a focus on enhancing operational efficiency and organic revenue growth [1][2]. Financial Performance - For the six months ending June 30, 2025, the company achieved revenue of RMB 482.0 million, a 31.7% increase from RMB 366.0 million in the first half of 2024 [1]. - The net profit under International Financial Reporting Standards (IFRS) was RMB 121.2 million, up 76.0% from the previous year's RMB 68.8 million [1]. - The adjusted non-IFRS net profit was RMB 131.4 million, reflecting a 68.1% increase from RMB 78.2 million in the first half of 2024 [1]. Research and Development - The company's R&D expenditure for the first half of 2025 was RMB 121.6 million, a 19.7% increase from RMB 101.5 million in the same period of 2024, driven by the introduction of more products and innovative solutions [1][2]. International Business Expansion - The international business generated revenue of RMB 15.7 million, a 36.9% increase compared to the same period in 2024, primarily from Europe and Asia [2]. - The company has established a presence in 27 countries/regions with 22 products, focusing on deepening its market penetration in Europe and expanding into emerging markets like Brazil, India, and South Africa [2]. Clinical Trials and Product Recognition - The company is conducting post-market clinical follow-up trials in Europe to establish product quality recognition, which is crucial for demonstrating clinical value and obtaining EU MDR certification [3]. - The products have gained recognition from leading hospital groups globally, including Asklepios and SANA, with over 31 products registered in more than 23 countries/regions [3].
归创通桥(02190.HK)公布中期业绩 溢利大幅增长76.0% 国际业务再创佳绩